STOCK TITAN
  1. Home
  2. Sec-filings
  3. ACRS
  4. [Form 4] Aclaris Therapeutics, Inc. Insider Trading Activity

Aclaris (ACRS) CMO vesting 36,375 RSUs with 9,330 shares tax withheld

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Aclaris Therapeutics, Inc. Chief Medical Officer Jesse Wayne Hall reported routine equity compensation activity involving restricted stock units (RSUs). On May 1, 2026, RSUs covering 36,375 shares were converted into common stock at a stated price of $0.00 per share, reflecting a vesting event rather than a market purchase.

On the same date, 9,330 common shares were withheld by Aclaris to cover Hall’s tax withholding obligations tied to the RSU vesting, a non‑market disposition classified as a tax-withholding transaction. After these events, Hall directly held 27,045 shares of common stock and 109,125 RSUs.

Each RSU represents a contingent right to receive one share of Aclaris common stock. The underlying RSUs vest in four equal installments on the first, second, third, and fourth anniversaries of May 1, 2025, subject to Hall’s continued service under the company’s 2024 Inducement Plan.

Positive

  • None.

Negative

  • None.
Insider Hall Jesse Wayne
Role Chief Medical Officer
Type Security Shares Price Value
Exercise Restricted Stock Units 36,375 $0.00 --
Exercise Common Stock 36,375 $0.00 --
Tax Withholding Common Stock 9,330 $4.41 $41K
Holdings After Transaction: Restricted Stock Units — 109,125 shares (Direct, null); Common Stock — 36,375 shares (Direct, null)
Footnotes (1)
  1. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. The transaction reported represents the withholding of shares by the issuer to satisfy the Reporting Person's tax withholding obligations in connection with the vesting and settlement of restricted stock units described in this Form 4. The shares underlying these restricted stock units vest in four equal installments on the first, second, third and fourth anniversaries of May 1, 2025, subject to the Continuous Service (as defined in the Issuer's 2024 Inducement Plan) of the Reporting Person as of each such date.
RSUs converted to common stock 36,375 shares RSU conversion to common stock on May 1, 2026
RSU conversion price $0.00 per share Stated transaction price for RSU conversion
Shares withheld for tax 9,330 shares Tax withholding disposition on May 1, 2026
Common shares held after transaction 27,045 shares Direct ownership after May 1, 2026 transactions
RSUs held after transaction 109,125 RSUs Remaining restricted stock units after conversion
RSU vesting schedule 4 equal installments Annually on May 1 from 2026 to 2029, subject to service
restricted stock unit financial
"Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer."
A restricted stock unit is a promise from a company to give an employee shares of stock after certain conditions are met, like staying with the company for a set amount of time. It’s like earning a bonus that turns into company stock once you’ve proven your commitment, making it a way to motivate and reward employees.
tax withholding obligations financial
"the withholding of shares by the issuer to satisfy the Reporting Person's tax withholding obligations in connection with the vesting"
Continuous Service financial
"subject to the Continuous Service (as defined in the Issuer's 2024 Inducement Plan) of the Reporting Person as of each such date."
2024 Inducement Plan financial
"as defined in the Issuer's 2024 Inducement Plan) of the Reporting Person as of each such date."
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Hall Jesse Wayne
(Last)(First)(Middle)
C/O ACLARIS THERAPEUTICS, INC.
701 LEE ROAD, SUITE 103
(Street)
WAYNE PENNSYLVANIA 19087
(City)(State)(Zip)
UNITED STATES
(Country)		2. Issuer Name and Ticker or Trading Symbol
Aclaris Therapeutics, Inc. [ ACRS ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director10% Owner
XOfficer (give title below)Other (specify below)
Chief Medical Officer
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
05/01/2026		6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock05/01/2026M36,375A(1)36,375D
Common Stock05/01/2026F(2)9,330D$4.4127,045D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Restricted Stock Units(1)05/01/2026M36,375 (3) (3)Common Stock36,375$0109,125D
Explanation of Responses:
1. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer.
2. The transaction reported represents the withholding of shares by the issuer to satisfy the Reporting Person's tax withholding obligations in connection with the vesting and settlement of restricted stock units described in this Form 4.
3. The shares underlying these restricted stock units vest in four equal installments on the first, second, third and fourth anniversaries of May 1, 2025, subject to the Continuous Service (as defined in the Issuer's 2024 Inducement Plan) of the Reporting Person as of each such date.
/s/ Matthew Rothman, Attorney-in-Fact05/05/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What insider transactions did Aclaris (ACRS) Chief Medical Officer report?

Jesse Wayne Hall reported RSU-related transactions on May 1, 2026. 36,375 restricted stock units converted into common stock, and 9,330 shares were withheld by Aclaris to cover tax obligations, reflecting routine compensation and tax events rather than open-market trading.

Did the Aclaris (ACRS) CMO sell shares in the open market in this Form 4?

No open-market sale occurred. Aclaris withheld 9,330 shares solely to satisfy Jesse Wayne Hall’s tax withholding obligations on RSU vesting. This tax-withholding disposition (code F) is a mechanical transaction, not a discretionary market sale of shares.

How many Aclaris (ACRS) shares and RSUs does the CMO hold after these transactions?

Following the May 1, 2026 transactions, Jesse Wayne Hall directly held 27,045 shares of Aclaris common stock and 109,125 restricted stock units. These RSUs each represent a contingent right to receive one share upon vesting, subject to continued service conditions.

What was the size of the RSU vesting event reported for Aclaris (ACRS) CMO?

The filing shows 36,375 restricted stock units converted into common stock at a stated price of $0.00 per share. This reflects a vesting and settlement of equity compensation, rather than a cash purchase, consistent with standard RSU-based executive compensation structures.

What are the vesting terms of the Aclaris (ACRS) CMO’s restricted stock units?

The RSUs vest in four equal installments on the first, second, third, and fourth anniversaries of May 1, 2025. Vesting is conditioned on Jesse Wayne Hall’s Continuous Service under Aclaris’s 2024 Inducement Plan on each applicable vesting date.